Enovis Files 8-K for Regulation FD Disclosure
Ticker: ENOV · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1420800
| Field | Detail |
|---|---|
| Company | Enovis Corp (ENOV) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, corporate-governance, compliance
TL;DR
**Enovis filed a routine 8-K for Regulation FD, no major news.**
AI Summary
Enovis Corporation filed an 8-K on January 8, 2024, primarily to disclose that it is furnishing information under Regulation FD. This filing indicates that Enovis is making certain information public, likely to avoid selective disclosure, but it does not contain new financial results or major corporate actions. For investors, this means the company is maintaining transparency, but the filing itself doesn't reveal new material information that would immediately impact the stock price, as it's largely a procedural update.
Why It Matters
This filing is largely procedural, indicating Enovis is making information public to comply with fair disclosure rules, rather than announcing a new event or financial results.
Risk Assessment
Risk Level: low — This 8-K is a standard disclosure under Regulation FD and does not indicate any new financial or operational risks for Enovis Corporation.
Analyst Insight
A smart investor would note this filing is routine and does not contain new material information requiring immediate action. It's a compliance update, not a catalyst.
Key Players & Entities
- Enovis Corporation (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- 001-34045 (string) — Commission File Number for Enovis Corporation
- ENOV (string) — trading symbol for Enovis Corporation Common Stock
- New York Stock Exchange (string) — exchange where Enovis Common Stock is registered
FAQ
What is the primary purpose of Enovis Corporation's 8-K filing on January 8, 2024?
The primary purpose of Enovis Corporation's 8-K filing on January 8, 2024, is to provide a Regulation FD Disclosure, as indicated under 'ITEM INFORMATION: Regulation FD Disclosure'.
What is the trading symbol and the exchange where Enovis Corporation's Common Stock is registered?
Enovis Corporation's Common Stock has the trading symbol 'ENOV' and is registered on the New York Stock Exchange, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address and phone number of Enovis Corporation as listed in the filing?
The business address of Enovis Corporation is 2711 Centerville Road, Suite 400, Wilmington, DE 19808, and its business phone number is (302) 252-9160, according to the 'BUSINESS ADDRESS' section.
What was Enovis Corporation's former company name and when did the name change occur?
Enovis Corporation's former company name was Colfax CORP, and the date of the name change was 20071210, as detailed in the 'FORMER COMPANY' section.
Under which SEC Act is this 8-K filing made?
This 8-K filing is made under the 1934 Act, as specified in the 'FILING VALUES' section under 'SEC ACT'.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-08 08:44:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ENOV New York Stock Excha
Filing Documents
- d104345d8k.htm (8-K) — 24KB
- d104345dex991.htm (EX-99.1) — 27KB
- g104345ex99_1s10g1.jpg (GRAPHIC) — 72KB
- g104345ex99_1s11g1.jpg (GRAPHIC) — 70KB
- g104345ex99_1s12g1.jpg (GRAPHIC) — 58KB
- g104345ex99_1s13g1.jpg (GRAPHIC) — 71KB
- g104345ex99_1s14g1.jpg (GRAPHIC) — 68KB
- g104345ex99_1s15g1.jpg (GRAPHIC) — 60KB
- g104345ex99_1s16g1.jpg (GRAPHIC) — 72KB
- g104345ex99_1s17g1.jpg (GRAPHIC) — 66KB
- g104345ex99_1s18g1.jpg (GRAPHIC) — 67KB
- g104345ex99_1s19g1.jpg (GRAPHIC) — 61KB
- g104345ex99_1s1g1.jpg (GRAPHIC) — 56KB
- g104345ex99_1s20g1.jpg (GRAPHIC) — 50KB
- g104345ex99_1s21g1.jpg (GRAPHIC) — 50KB
- g104345ex99_1s22g1.jpg (GRAPHIC) — 57KB
- g104345ex99_1s23g1.jpg (GRAPHIC) — 46KB
- g104345ex99_1s2g1.jpg (GRAPHIC) — 141KB
- g104345ex99_1s3g1.jpg (GRAPHIC) — 72KB
- g104345ex99_1s4g1.jpg (GRAPHIC) — 50KB
- g104345ex99_1s5g1.jpg (GRAPHIC) — 74KB
- g104345ex99_1s6g1.jpg (GRAPHIC) — 49KB
- g104345ex99_1s7g1.jpg (GRAPHIC) — 74KB
- g104345ex99_1s8g1.jpg (GRAPHIC) — 62KB
- g104345ex99_1s9g1.jpg (GRAPHIC) — 75KB
- 0001193125-24-003983.txt ( ) — 2280KB
- enov-20240108.xsd (EX-101.SCH) — 3KB
- enov-20240108_lab.xml (EX-101.LAB) — 18KB
- enov-20240108_pre.xml (EX-101.PRE) — 11KB
- d104345d8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. As previously announced, Enovis Corporation's Chair and Chief Executive Officer, Matt Trerotola, and Chief Financial Officer, Ben Berry, will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 a.m. PST (12:45 p. m. EST). A link to the live webcast presentation will be available on www.enovis.com . A link to a replay of the presentation will also be available on the Enovis website later in the day. A copy of the presentation materials is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished to the Securities and Exchange Commission ("SEC") and shall not be deemed to be incorporated by reference into any of Enovis' filings with the SEC under the Securities Act of 1933, as amended.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 99.1 Presentation dated January 8, 2024 104 Cover Page Interactive Data File – The cover page from this Current Report on Form 8-K is formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 ENOVIS CORPORATION By: /s/ Phillip B. Berry Name: Phillip B. Berry Title: Senior Vice President and Chief Financial Officer